News Focus
News Focus
icon url

Dr Bala

02/06/23 1:15 AM

#565191 RE: HyGro #565182

NWBO has the best trial results in history and is sure to get approvals from all the RAs. Thanks so much, HyGro.

icon url

Roman516

02/06/23 11:38 AM

#565298 RE: HyGro #565182

H-G, Dr. Linda Liau and her team at UCLA seem to contradict your comments.
" There is unmet need for all tumor types. Question is are NWBO results real after all the bias built into the trial."

Guess you don't understand who the helmet works per your comments.
"Guess you don't know the Optune device -- adhesive patches that are placed on the head, called transducer arrays. No "metal helmet", just adhesive fabric."
The helmet incorporates multiple transducers
https://www.med.unc.edu/neurosurgery/new-wearable-device-uses-electric-fields-to-treat-glioblastomas/
"Wearable Device to Treat Brain Cancer by Using Electrical Stimulation"
THERE ARE MANY SIDE EFFECTS
https://www.verywellhealth.com/optune-5072947

Device: Optune®
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.
https://clinicaltrials.gov/ct2/show/NCT04471844

The good news is that Dr. Linda Liau will "teach up to 1,000 SNO-EANO neurologists, neuro-oncologists, oncologists, neurosurgeons & other KOLs in the US & Europe about the $NWBO #DCVax-L Phase 3 trial results on 2/14/23 (Valentine’s Day):"

Source: ATLnsider, POST # 565093, Sunday, February 05, 2023 5:10:16 PM
https://neuro-onc-academy.org/content/highlights-sno-eano-2022-annual-meetings#group-tabs-node-course-default2

Per H-G comments,
"Optune is approved, DCVax-L isn't, so until it gets approved if it does, Optune is the most efficacious choice."
Many are praying for DCVax-L to be approved and with near zero side effects, perhaps the time is near that the helmet will take a back seat to DCVax-L, IMPO.
Bullish
Bullish